

Supplementary Appendix 4: SARS-CoV-2 IgG spike, RBD, and NP antibody response following mRNA-1273 or BNT162b2 vaccination in hemodialysis patients excluding patients with positive COVID-19 RT-PCR or anti-NP antibody

Note: NP=nucleocapsid protein, RBD=receptor binding domain.

Note: Patients were excluded if they had a positive RT-PCR for SARS-CoV-2 or anti-NP seroconversion at any point

Note: Hemodialysis patients received either the mRNA-1273 or the BNT162b2 vaccine. Serologic assessments were taken at 6-7 weeks and 12 weeks post two-dose vaccination and the 0.00625 dilution is represented.

Note: Sample sizes were as follows: mRNA-1273 6-7 weeks (n=76), BNT162b2 6-7 week (n=57), mRNA-1273 12 weeks (n=65), BNT162b2 12 weeks (n=108).

Note: Dots represent individual serum samples collected. Individuals with prior RT-PCR confirmed SARS-CoV-2 infection are indicated in green.

Note: Antibody levels are reported as relative ratios to synthetic standards. Seroconversion threshold represents a positive test and are 0.19, 0.186, and 0.396 for anti-spike, anti-RBD, anti-NP antibodies, respectively and is indicated by the dashed line for each antibody. Median levels are indicated by the red line for each antibody.

Note: The median level of antigen in convalescent serum is from a cohort of 211 patients in the general population with prior COVID-19 of all severities represents a robust antibody response: 1.38, 1.25, and 1.13 for anti-spike, anti-RBD, and anti-NP antibodies, respectively and is indicated by the green line for each antibody.

Appendix 4, as supplied by the authors. Appendix to: Yau K, Chan CT, Abe KT, et al. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. *CMAJ* 2022. doi: 10.1503/cmaj.211881. Copyright © 2022 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.

Appendix 4, as supplied by the authors. Appendix to: Yau K, Chan CT, Abe KT, et al. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. *CMAJ* 2022. doi: 10.1503/cmaj.211881. Copyright © 2022 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.